

Dendreon Corporation

1301 2nd Avenue
Seattle, WA 98101 USA

tel 206-256-4545
fax 206-256-0571

www.dendreon.com

November 10, 2014

Dear Valued Customer,

I am reaching out to you to provide an important update regarding Dendreon. We have recently announced that Dendreon has reached agreements with certain of its senior noteholders on the terms of a financial restructuring. The agreements will enable continued delivery of PROVENGE® (sipuleucel-T) without disruption or impact to access for providers and appropriate patients in need of this revolutionary personalized immunotherapy treatment.

Under the terms of the agreements, the financial restructuring may take the form of a stand-alone reorganization or a sale of Dendreon to a party that would continue producing and providing PROVENGE. In order to implement the terms of the agreements, Dendreon and its U.S. subsidiaries have filed for voluntary reorganization under Chapter 11 of the Bankruptcy Code in Wilmington, Delaware.

It is important to understand that this is a financial restructuring to address our debt, not a liquidation of the business— Dendreon’s operations will continue in the ordinary course and PROVENGE will remain available. In fact, you may be familiar with other companies that have successfully gone through Chapter 11 and emerged in strong positions such as General Motors, Delta Airlines or, in the pharmaceutical industry, K-V Pharmaceutical.

We have taken the necessary steps in preparation for this financial restructuring and the most important things for you to know about this process are:

- **PROVENGE is and will continue to be available for patients.** We have sufficient liquidity to support our operations and we intend to continue to operate in the ordinary course during the restructuring and sale process. This includes the continued availability of Dendreon On Call and our best in class patient access and assistance programs.
- **We expect to continue to support all Dendreon-sponsored clinical trials and investigator-initiated studies (IITs) at this time.** Ongoing trials currently enrolling patients remain open for accrual and continue to be monitored for long term follow up under the terms of all of our contractual agreements.
- **We are taking the steps necessary to ensure that our customer programs and agreements will continue uninterrupted through this process.** We fully expect to service distributors and wholesalers to

ensure timely fulfillment of orders and shipments and to meet other obligations to physicians and patients who depend on PROVENGE.

- **Our primary focus continues to be on executing on our mission to serve our physician customers and your patients with excellence.**

If you have additional questions, please do not hesitate to contact your regular Dendreon representative. You can access additional information about the process, court documents, etc., through Dendreon's claims agent at <https://cases.primeclerk.com/dendreon> or 844-794-3479.

We believe that these agreements allow us to focus on the clinical merits of PROVENGE and the important role immunotherapy plays in the treatment of advanced prostate cancer.

Thank you for your continued support.

Sincerely,

A handwritten signature in black ink that reads "W. Thomas Amick". The signature is written in a cursive, flowing style.

W. Thomas Amick
President and Chief Executive Officer